First-of-its-kind global collaboration launched to develop transformative treatment regimens for tuberculosis

  • Today a consortium of philanthropic, non-profit and private sector organizations launched a collaboration that aims to accelerate the development of novel “pan-TB” drug regimens for the treatment of tuberculosis (TB) that are ready for phase 3 development. The regimens will be designed to have little to no drug resistance and an acceptable safety profile, and be better-tolerated, shorter in duration and simpler to use than existing options. Such regimens are intended to be a central component of efforts to address the current complexities and challenges of TB treatment. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter

    Du magst vielleicht auch